CHEK1 and cancer: Accordingly, BRAFV600E-mutant cancer cells and organoids were shown to be sensitive to combinations of CHK1 inhibitors and chemically induced replication stress by means of low doses of hydroxyurea, suggesting the use of HU/CHK1 inhibition as a treatment option for BRAFV600E-mutant multi-therapy-resistant CRCs.